Systematic Reviews
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 16, 2022; 10(20): 6900-6914
Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6900
Network pharmacology-based strategy for predicting therapy targets of Sanqi and Huangjing in diabetes mellitus
Xiao-Yan Cui, Xiao Wu, Dan Lu, Dan Wang
Xiao-Yan Cui, Hebei Institute for Drug and Medical Device Control, Shijiazhuang 050011, Hebei Province, China
Xiao Wu, Department of Basic Medical, HE’s University, Shenyang 110163, Liaoning Province, China
Dan Lu, College of Clinical, HE’s University, Shenyang 110163, Liaoning Province, China
Dan Wang, College of Human Kinesiology, Shenyang Sport University, Shenyang 110102, Liaoning Province, China
Author contributions: Wang D and Lu D performed the writing and revising of the manuscript; Wu X and Cui XY contributed to the design of the work and performed overall supervision; Wang D wrote and revised the paper.
Supported by the Central Government guides local S&T Program of Hebei Province, No. 216Z2501G; and Scientific Research Project of Hebei Provincial Market Supervision Administration, No. 2021YJ11.
Conflict-of-interest statement: The authors declare no conflict of interest, financial or otherwise.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dan Wang, PhD, Teacher, College of Human Kinesiology, Shenyang Sport University, No. 36 Jinqiansong East Road Sujiatun District, Shenyang 110102, Liaoning Province, China. 595680903@qq.com
Received: December 28, 2021
Peer-review started: December 28, 2021
First decision: January 23, 2022
Revised: February 2, 2022
Accepted: April 15, 2022
Article in press: April 15, 2022
Published online: July 16, 2022
Processing time: 188 Days and 18.3 Hours
ARTICLE HIGHLIGHTS
Research background

Sanqi and Huangjing (SQHJ) ameliorate diabetes mellitus (DM) in vivo and in vitro respectively. However, the combined effects of SQHJ on DM are unclear.

Research motivation

To provide an objective basis for the treatment of DM with traditional Chinese medicine.

Research objectives

To explore the potential mechanism of Panax notoginseng (Sanqi in Chinese) and Polygonati Rhizoma (Huangjing in Chinese) for the treatment of DM using network pharmacology.

Research methods

Active components of SQHJ and targets were predicted and screened by network pharmacology using the Traditional Chinese Medicine Systems Pharmacology Analysis Platform, DisGeNET database, STRING database, Gene Ontology (GO) function and Kyoto Encyclopedia of Genes and Genomes enrichment analysis.

Research results

Of 18 active components from 157 SQHJ components, 187 potential targets for active components and 115 overlapping genes for active components and DM were screened. Quercetin, beta-sitosterol, baicalein and so on were the major active components. The mechanism of intervention of SQHJ in treating DM may involve nine core targets (TP53, AKT1, CASP3, TNF, interleukin-6, PTGS2, MMP9, JUN, and MAPK1). The treatment of DM using SQHJ primarily involved 16 GO enriched terms and 13 related pathways.

Research conclusions

SQHJ treats DM by targeting TP53, AKT1, CASP3, and TNF and participating pathways in leishmaniasis, pathways in cancer, and so on.

Research perspectives

SQHJ is effective for the treatment of DM. In the future, experiments will be needed to verify these results.